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Background: Many studies support that chemokine (C-X-C motif) ligand 1 (CXCL1) regulate tumor epithelial-stromal
interactions involving in tumor growth and invasion. However, limited studies have been conducted on the expression
and function of the CXCL1 gene in hepatocellular carcinoma (HCC).
Methods: The mRNA and protein level expression of CXCL1 was examined in HCC tissues and cell lines. The
expression of CXCL1 was correlated with clinicopathological features and follow-up data. Overexpression approaches
were used to evaluate the biological functions of CXCL1 by MTT and matrigel invasion assays. Protein expression levels
of CXCL1 and P65 were determined by western blot analysis.
Results: In this study, we found that CXCL1 expression was markedly upregulated in HCC tissues. Ectopic expression of
CXCL1 significantly promoted HCC cells proliferation and invasion. Furthermore, CXCL1 promote cell invasion through
NF-kB-dependent pathway. CXCL1 expression in HCC associated with clinical stage (P = 0.034) and distant metastasis
(P = 0.028). Moreover, Patients with high CXCL1 expression level had poorer overall survival (OS;P = 0.027) than those
with low CXCL1 expression.
Conclusions: These data indicated that the CXCL1 upregulation may contribute to both the development and
progression of HCC and this effect may be associated with increased proliferation and invasiveness mainly via
regulating P65 expression.
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HCC is the third most leading cause of cancer death, and
is the most common malignancy in eastern Asia, sub-
Saharan Africa [1,2]. Although significant advances have
been made in surgery and chemotherapy, radiation, the
improvement in long-term prognosis of patients with
HCC in recent years is still unfavorable [3,4]. A hallmark
of the malignant phenotype is the uncontrolled of cell pro-
liferation and invasive phenotype that allows cancer cells
to survive [5,6]. Therefore, a better understanding of the
key factors in these processes is great demand to predict* Correspondence: wanxj99@163.com; quleiline@sina.com
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ive therapies for high-risk population.
Chemokines are known to be crucial mediators of the
inflammatory response and chemokines altered may result
in the initiation and progression of cancers [7-9]. CXCL1,
a member of the CXC group of chemokines family of pro-
teins, was initially cloned from fibroblasts [10]. Previous
results showed that CXCL1 could contribute to inflamma-
tion response in the development of Alzheimer’s disease
and CXCL1 forcing-expression could induce angiogenesis
through the ERK1/2 and EGF pathways [11,12]. Its func-
tions imply that CXCL1 is associated with tumor progres-
sion including tumor growth, angiogenesis and metastasis.
Recent studies have revealed that CXCL1 is highly
expressed in melanoma, breast cancer and bladder cancer
[13-15]. However, there have been no reports on the gene
function and prognosis associated with CXCL1 in HCC.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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development and progression of cancer such as prolifera-
tion, migration and invasion [16]. Previous study have
shown that NF-kB activation enhance HCC cell migration
and invasion. But the molecular mechanism(s) by which
CXCL1 contributes to the malignant phenotype of HCC
via the NF-κB pathway has not been fully elucidated.
In our current study, we showed the first evidence that
CXCL1 was significantly up-regulated in HCC compared
with matched adjacent non-cancerous liver tissues. The
relationships with between CXCL1 expression and clinic
pathological characters and the relapse-free survival after
resection were further analyzed. Overexpression of CXCL1
in SMMC-7721and Bel-7402 cells enhanced cell prolifera-
tion and invasion. Mechanistically, we show for the first
time that P65 is required for cell invasion. Our findings
suggest that CXCL1 may represent a novel indicator of
poor prognosis in HCC and may be a potential therapeutic
target for gene therapy.Materials and methods
Tissue samples
As previously described, 48 primary HCC specimens and
normal adjacent tissues were collected from patients who
underwent complete resection at the Shanghai First
People’s Hospital between Dec 2004 and May 2007 and
were diagnosed with hepatic carcinoma (HCC) using histo-
logical diagnoses [17]. No local or systemic treatment had
been received in these patients before surgical resection.
Written informed consent was obtained from all patients
involved in the study. This study was performed with the
approval of the Medical Ethical Committee of Shanghai
First People’s Hospital and the ethical guidelines of the
Declaration of Helsinki. All of the tissue samples were
flash-frozen in liquid nitrogen immediately after collection
and stored at −80°C until RNA was extracted.Cell culture and treatment
The human hepatoma cell lines (SMMC-7721, Bel-
7402, Hep3B and MHCC-97H) and non-malignant liver
cells (LO2) were purchased from the Shanghai Cell
Bank of the Chinese Academy of Sciences (Shanghai,
China) and cultured in High glucose Dulbecco’s
Modified Eagle Medium (DMEM) (HyClone, Shanghai,
China) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen, Carlsbad, CA, USA), with 100 U/ml
of penicillin G and 100 μg/ml of streptomycin at 37°C
in a water-saturated atmosphere of 5% CO2. For studies
assessing the effect of NF-κB inhibition, cells were
treated the NF-κB inhibitor ammonium pyrrolidine-
dithiocarbamate (PDTC) (Sigma-Aldrich, Poole, UK) at
a final concentration of 20 μM.RNA extraction and qRT-PCR analyses
As previously described [17], total RNA was isolated from
HCC tissue specimens and cultured cells with TRIzol Re-
agent (Invitrogen) and then converted to first strand cDNA
using iScript™ cDNA Synthesis Kit (Bio-Rad, CA, USA) ac-
cording to the manufacturer’s instructions. Real-time quan-
titative reverse-transcription polymerase chain reaction
(qRT-PCR) was carried out using the SYBR Green PCR
Master Mix (Toyobo, Osaka, Japan) according to the man-
ufacturers’ instructions by an ABI 7900HT real-time PCR
system (Applied Biosystems, Foster City, CA, USA) and
amplified with target gene specific primers. The primer
sequences were as follows: 5′-GCCCAAACCGAAGTCAT
AGC-3′(sense) and 5′-GGCACAATCCAGGTGGCC-3′
(antisense) for CXCL1; 5′-ACCCAGAAGACTGTGGATG
G-3′(sense) and 5′-CAGTGAGCTTCCCGTTCAG-3′(anti-
sense) for GAPDH. GAPDH was used as a loading control.
The PCR reaction contained an initial denaturation at 95°C
for 2 min, followed each PCR cycle by de-naturation at 95°C
for 1 min, annealing and extension at 72°C for 1 min for a
total of 40 cycles. All experiments were performed in tripli-
cate with three technical replicates.
Plasmid construction and cell transfection
To overexpression of CXCL1, we obtained the coding
sequence (CDS) fragment of CXCL1 by PCR using the
following primers: forward, 5′-CCCAAGCTTATGGCC
CGCGCTGCTCTC-3′ and reverse, 5′-AAAGGATCCT
CAGTTGGATTTGTCACTGTTCA-3′ (including HindIII
and BamHI sites with underline, respectively). The resulting
PCR product was then subcloned into pCDNA3.1 (+)
vector (Invitrogen) and named it pCDNA3.1-CXCL1. The
sequence of CXCL1 was confirmed by DNA sequencing
(Sangon, Shanghai, China). Subconfluent cells were trans-
fected with CXCL1 or empty vectors using X-tremeGENE
(Roche, Basel, Switzerland) according to the manufacturer’s
protocol. The expression of CXCL1 protein was confirmed
48 hours after transfection by western blot analyses.
Cell proliferation and invasion assays
Cell proliferation assay was performed as recently de-
scribed [17]. Briefly, differences in the proliferative capacity
of 7721 and 7402 cells with or without overexpression of
CXCL1 were examined by the absorbance using coulter
counter (Beckman Coulter, CA, USA).
For the invasion assays, 24 hours after transfection, 3 ×
104 cells in 100 μl serum-free media were added to the
upper chamber of an insert (8-μm pore size, millepore)
coated with Matrigel (BD, San Diego, CA, USA). 600 μl
media containing 10% FBS were added to the lower cham-
ber. After incubation for 24 hours, the cells remaining on
the upper membrane were removed with a cotton swab,
whereas the cells that had invaded through the membrane
were fixed and stained with methanol and 0.1% crystal
Figure 1 Expression of CXCL1 in HCC tissue samples and HCC cell lines. (A) Determining the mRNA expression of CXCL1 in 48 cases of HCC
tissues and corresponding nontumor tissues. (B) CXCL1 mRNA levels was measured by qRT-PCR as indicated HCC cell lines. (C) The protein
expression levels of CXCL1 were determined by Western blot analysis in HCC cell lines. GAPDH was used as a loading control *P < 0.05, **P < 0.01.
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randomly selected fields using an IX71 inverted micro-
scope (Olympus, Tokyo, Japan). Experiments were inde-
pendently repeated in triplicate.
Western blot analysis
As described before [17], aliquots of 40 μg of protein from
each group was separated by 13% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto a 0.22-
μm polyvinylidene difluoride (PVDF) membrane (Millipore,
Bedford, MA, USA). After blocking with 5% nonfat milk in
TBS + 0.05% Tween™ 20 for 1 hour at room temperature,
membranes were incubated with an Rabbit Anti-CXCL1
antibody (Proteintech, Chicago, IL, USA), Rabbit Anti-
Phospho-NF-κB p65 (Ser536) antibody, Rabbit Anti-
NF-κB P65 antibody (Cell signaling Technology,
Beverly, MA, USA), or Anti-GAPDH (Bioworld,
Nanjing, China) overnight at 4°C. Densitometric levelsFigure 2 Representative immunohistochemical staining of CXCL1 in H
(A), moderate staining of CXCL1 (B), nearly negative staining of CXCL1 (C)of CXCL1 signals were quantified and expressed as
their ratio to GAPDH.
Immunohistochemistry
Immunohistochemical analyses were performed as de-
scribed previously [17], paraffin-embedded tumor spec-
imens were cut into 4-μm-thick sections and mounted
on silane-coated slides. The slides were then treated
with a graded series of ethanol solution. 3% H2O2 was
applied to block endogenous peroxide activity for
15 min at room temperature. Antigen retrieval was
performed at 95°C in 0.01 M sodium citrate buffer
(pH 6.0) for 30 min and sections were blocked with
normal goat serum. The sections were then incubated
with a primary antibody against CXCL1 (Proteintech)
in a humidity chamber at 4°C overnight. After washing
with phosphate-buffered saline (PBS), the slides were
incubated for 60 min with the DAKO Envision+/HRPCC tissue. Representative image showed strong staining of CXCL1
in HCC samples. All images were captured at 100× magnification.
Table 1 Correlation between CXCL1 expression and
clinicopathologic parameters of HCC
Parameters Cases CXCL1 expression P value
Positive (%) Negative
Gender
Male 41 29 (60.1%) 12 0.662
Female 7 4 (57.1%) 3
Age
< 50 24 13 (54.2%) 11 0.556
≥ 50 24 16 (82.8%) 8
Tumor diameter
< 5 cm 35 21 (55.4%) 14 1
≥ 5 cm 13 8 (66.7%) 5
Tumor number
Single 28 13 (46.4%) 15 0.394
Multiple 20 12 (60.0%) 8
Preoperative AFP(ng/mL)
<20 19 8 (57.9%) 11 0.377
≥20 29 17 (58.6%) 12
Liver capsule
Yes 31 11 (35.5%) 20 0.071
No 17 11 (64.7%) 6
Distant metastasis
Yes 9 7 (77.8%) 2 0.028
No 39 13 (35.6%) 26
Clinical TNM stage
I-II 37 12 (51.4%) 25 0.034
III-IV 11 8 (72.7%) 3
Abbreviations: AFP, alpha fetoprotein. One-way Analysis of Variance (ANOVA)
test was performed.
Figure 3 Kaplan-Meier analysis of HCC survival rates in relation
to CXCL1 protein expression. Overall survival rates of patients with
high (n = 33) and low (n = 15) CXCL1 expression.
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stained with hematoxylin. Negative control sections
were incubated with normal rabbit IgG instead of a
specific primary antibody.
Statistical analyses
Data are presented as the mean ± standard deviation
(SD) from at least three independent experiments. Stu-
dent’s t test was employed to assess the differences
between two groups and one-way analysis of variance
(ANOVA) was used to analyze significant differences
among three groups. Survival was determined using the
Kaplan-Meier method, and the significance of the dif-
ference was evaluated using the log-rank test. P < 0.05
was considered to be statistically significant. All statis-
tical analyses were performed with GraphPad Prism 5.0
software (La Jolla, CA, USA).
Results
CXCL1 is up-regulated in HCC tissues and cell lines
It has been recently reported that CXCL1 is high expressed
in melanoma, breast cancer and could be associated with
tumor differentiation grade and disease-specific survival of
bladder tumors [12,13,15]. To determine CXCL1 expres-
sion in HCC tissues, we use qRT-PCR to analyze mRNA of
CXCL1 in 48 HCC tissues and marched adjacent non-
cancerous tissue. The level of CXCL1 mRNA was signifi-
cantly increased in cancerous tissues compared with
corresponding non-cancerous tissues (p < 0.01) (Figure 1A).
To confirm the association between the expression of
CXCL1 and HCC, four human HCC cell lines (SMMC-
7721, Bel-7402, Hep3B and MHCC-97H) and a normal
liver cell (LO2) were selected to detect the expression
levels of CXCL1 mRNA and protein by qRT-PCR and
western blot. Among the five cell lines analyzed, CXCL1
mRNA levels were found higher expression in HCC
cells compared to LO2 cells (Figure 1B). Consistent
with the results of mRNA, a significant increase in
CXCL1 protein levels was also found in HCC cells as
assessed by western blot (Figure 1C). These data indi-
cate that abnormal CXCL1 might play important roles
in HCC tumorigenesis.
CXCL1 expression in HCC associated with clinical stage
and distant metastasis
Increased expression of CXCL1 in HCC tissues was fur-
ther confirmed by immunochemistry (IHC) staining using
an antibody to CXCL1. Representative images of positive
expression of CXCL1 IHC staining were show in Figure 2.
Then we determined the association of CXCL1 expression
level and clinicopathological implications of 68 HCC
patients in Table 1. The results demonstrated that high
CXCl1 expression was significantly associated with
advanced clinical stages (p = 0.034) and distant metastasis
Figure 4 The effect of CXCL1 on cell proliferation and invasion in 7721 and 7402 cell lines. (A) CXCL1 and p-P65 expression in the control
and CXCL1-transfected cells was determined by Western blotting. GAPDH was used as a loading control. (B and C) Cell proliferation of CXCL1
was assessed in 7721 and 7402 cells by MTT at the indicated time. (D) Representative images of cells with or without CXCL1 transfection that had
migrated into the lower chamber were shown. Quantitative analysis of cell invasion was assessed by invasion assay.
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between CXCL1 expression and patient age, gender, tumor
diameter, tumor number, AFP, and liver capsule.
Over-expression of CXCL1 in HCC is associated with poor
prognosis
We further examined whether CXCL1 expression level
correlated with prognosis of HCC patients after surgery
resection. Overall survival (OS) curves were plotted
according to CXCL1 expression level by the Kaplan–Meier
analysis and log-rank test, and the results were presented
in Figure 3. Remarkably, CXCL1-positive expression
indicated a shorter overall survival time of patients
(median OS: 39 months) compared with CXCL1-negative
expression (median OS: 64 months). These results to-
gether suggested upregulated expression of CXCL1 inFigure 5 P65 involved in CXCL1-induced cancer cell invasion. (A) Effec
p-P65 in 7721 and 7402 transfected with CXCL1. (B) HCC cells 7721 and 74
(100 μm) for 6 hours and showed reduced invasion activity compared withHCC was significantly correlated with patients’ survival
time.
CXCL1 overexpression induced cell proliferation and
invasion in HCC cells
To further address the biological role of CXCL1 in HCC,
we investigated the effect of overexpression of CXCL1 on
cell proliferation and invasion. The over-expressed cell
lines were named as 7721-CXCL1 or 7402-CXCL1, while
the matched control cell lines were named as 7721-vector
or 7402- vector, respectively. As measured by western
blotting analysis, two HCC cell lines 7721 and 7402 trans-
fected with pCDNA3.1-CXCL1 had at least 4-fold higher
levels of CXCL1 than the control (Figure 2A). MTT assay
revealed that cell growth was significantly increased in
CDNA3.1-CXCL1 transfected 7721 cells and 7402 cellst of NF-κB inhibitors on CXCL1-induced the protein expression of
02 transfected with CXCL1 were treated with or without PDTC
the negative control.
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7721-CXCL1 and 7402-CXCL1 cells was significantly
enhanced compared to 7721-vector or 7402- vector,
respectively (p < 0.01, Figure 4D).CXCL1 promote cell invasion through NF-κB-dependent
pathway
Cancer cell invasion is key step in metastasis that is a pri-
mary cause of cancer-related death. Since that CXCL1
were shown to be important for HCC cell proliferation
and invasion, we sought to key signaling pathway respon-
sible for CXCL1-induced cell invasion. It has been
previously shown that CXCL1 increases cell migration
and invasion through NF-κB/HDAC1 epigenetic regula-
tion in prostate cancer [18], and it has also been previ-
ously established that nuclear factor-kappa B (NF-κB)
positively medicated the expression of CXCL1 through
binding to the CXCL1 promoter in melanoma cells [19].
Therefore, we sought to determine whether NF-κB was re-
quired for CXCL1-induced cell proliferation and invasion.
Consistent with previous reports [18], we observed a
marked increase in p-P65 protein levels in 7721-CXCL1
and 7402-CXCL1 cells (Figure 5A). To investigate whether
NF-κB signaling pathway plays a crucial role in CXCL1-
induced cell invasion in HCC cells, we blocked NF-κB
pathway of 7721-CXCL1 and 7402-CXCL1 cells using
NF-κB inhibitor, PDTC (Figure 5A). Our results demon-
strated that the stimulatory effects of CXCL1 on cell
invasion were significantly extenuated by specific inhib-
ition of PDTC (Figure 5B), suggesting that CXCL1
activated NF-κB pathway play a critical role in CXCL1-
enhanced cell invasion.Discussion
Overexpression of CXCL1 has been found in various
cancers and correlates with poor prognosis [12,15,20,21].
However, recent studies have shown that CXCL1 nega-
tively associated with non-small cell lung cancers, but its
biological functions were not further explored [22].
However, little is known about the functional role of
CXCL1 in HCC. We are, to our knowledge, the first
group evaluating the expression and prognostic impact
of CXCL1 in HCC.
In our present study, we found that the mRNA level
CXCL1 was significantly increased in HCC tissues
compared to matched normal tissues, which suggests that
CXCL1 may promote tumor growth in HCC. Consistent
with pervious results, the upregulation of CXCL1 was ob-
served in HCC cells compared to a non-malignant liver
cell-LO2 both at mRNA and protein levels. Similar results
were also observed in other human cancer, such as colon,
skin, bladder cancers, prostate cancer, and breast cancers
[13-15,18,23], in which the overexpression of the CXCL1gene was often observed and involved in inflammatory en-
vironment to cancer initiation. It is plausible that overex-
pression of CXCL1 may play an important role in HCC
tumorigenesis. Further correlation analyses indicated that
the high expression of CXCL1 was significantly correlated
with clinical stage and distant metastasis of HCC patients,
suggesting that high CXCL1 expression might associate
with the progression of HCC. In addition, the overall sur-
vival of patients with high CXCL1 was lower than that of
patients with low CXCL1.
With regard to the gene function, we used 7721 and
7402 cell lines with low CXCL1 to establish useful method
for investigating the biological functions and potential
mechanisms underlying the growth and invasion of HCC
cells. Overexpression of CXCL1 in 7721 and 7402 cells sig-
nificantly increased cell growth/proliferation. In addition,
Overexpression of CXCL1 also enhanced cell invasion.
This result was consist with previous studies that showed
that CXCL1 was involved in cell proliferation or/and
tumor metastasis. Taken together, these data indicated that
CXCL1 may be involved in carcinogenesis and develop-
ment of HCC, and act as an oncogene in HCC.
The role of NF-κB has been reported to regulate the ex-
pressions of many genes which were associated with sev-
eral aspects of tumor progress, including cell proliferation,
migration, invasion, apoptosis and angiogenesis [24,25].
Interestingly, CXCL1-induced nuclear translocation of
NF-κB have been shown to play a crucial role in CXCL1-
mediated cell progression [18]. Other studies found that
NF-κB integrated the promoter of CXCL1 and enhanced
the expression of CXCL1 [19]. Then we focused on
CXCL1/ NF-κB signaling pathway in HCC. As we ex-
pected, CXCL1 overexpression resulted in NF-κB activity
that was critical for promoting malignant behavior of
HCC cells. Furthermore, our findings showed that cells
treated with an NF-κB inhibitor PDTC attenuated
CXCL1-induced cell invasion. These results suggested that
overexpression of CXCL1 enhances activation of the NF-
κB pathway and that it cooperates with this pathway to
stimulate proliferation and invasion.
Taken together, our findings provided the first evidence
that CXCL1 was significantly increased in HCC tissues
and also revealed novel insights into the mechanism that
there exists a CXCL1/ NF-κB positive feedback loop in
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